DCOY Share Price Performance
US$2.67
-60.81 (-95.79%)
Price US$2.67
Share Pricen/a
Decoy Therapeutics Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
DCOY Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Decoy Therapeutics Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -22.05
- -718.10%
- -6,347.85%
- 0%
About DCOY
- Founded
- n/a
- Employees
- 11
- CEO
- WebsiteView website
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company’s IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
